Containment of bioaerosol infection risk by the Xpert MTB/RIF assay and its applicability to point-of-care settings.
about
Xpert® MTB/RIF assay: development, evaluation and implementation of a new rapid molecular diagnostic for tuberculosis and rifampicin resistanceXpert® MTB/RIF assay for pulmonary tuberculosis and rifampicin resistance in adultsXpert® MTB/RIF assay for pulmonary tuberculosis and rifampicin resistance in adultsXpert MTB/RIF test for detection of pulmonary tuberculosis and rifampicin resistancePoint-of-care diagnosis of tuberculosis: past, present and futureTime to treatment and patient outcomes among TB suspects screened by a single point-of-care xpert MTB/RIF at a primary care clinic in Johannesburg, South AfricaFeasibility, diagnostic accuracy, and effectiveness of decentralised use of the Xpert MTB/RIF test for diagnosis of tuberculosis and multidrug resistance: a multicentre implementation studyRapid molecular detection of tuberculosis and rifampin resistanceDiagnostic accuracy of Xpert MTB/RIF for extrapulmonary tuberculosis specimens: establishing a laboratory testing algorithm for South AfricaDiagnostic accuracy of nucleic acid amplification tests (NAATs) in urine for genitourinary tuberculosis: a systematic review and meta-analysis.Performance characteristics of the Cepheid Xpert MTB/RIF test in a tuberculosis prevalence surveyPerformance evaluation of the Xpert MTB/RIF assay according to its clinical application.Impact of GeneXpert MTB/RIF assay on triage of respiratory isolation rooms for inpatients with presumed tuberculosis: a hypothetical trialSensitive multiplex PCR assay to differentiate Lyme spirochetes and emerging pathogens Anaplasma phagocytophilum and Babesia microti.Cepheid GeneXpert MTB/RIF assay for Mycobacterium tuberculosis detection and rifampin resistance identification in patients with substantial clinical indications of tuberculosis and smear-negative microscopy resultsXpert MTB/RIF: a new pillar in diagnosis of extrapulmonary tuberculosis?The Application of GeneXpert MTB/RIF for Smear-Negative TB Diagnosis as a Fee-Paying Service at a South Asian General Hospital.Reporter phage and breath tests: emerging phenotypic assays for diagnosing active tuberculosis, antibiotic resistance, and treatment efficacy.Testing Pooled Sputum with Xpert MTB/RIF for Diagnosis of Pulmonary Tuberculosis To Increase Affordability in Low-Income Countries.Bacterial Loads Measured by the Xpert MTB/RIF Assay as Markers of Culture Conversion and Bacteriological Cure in Pulmonary TB.Scaling up Xpert MTB/RIF technology: the costs of laboratory- vs. clinic-based roll-out in South Africa.The cost-effectiveness of routine tuberculosis screening with Xpert MTB/RIF prior to initiation of antiretroviral therapy: a model-based analysis.Assessing the utility of Xpert(®) MTB/RIF as a screening tool for patients admitted to medical wards in South Africa.Diagnostic Accuracy of Xpert Test in Tuberculosis Detection: A Systematic Review and Meta-analysis.Xpert MTB/RIF Results in Patients With Previous Tuberculosis: Can We Distinguish True From False Positive Results?Haemoptysis in a female with diabetes mellitus: a unique presentation of chronic pulmonary aspergillosis, pulmonary tuberculosis, and Klebsiella peumoniae co-infection.Advances in tuberculosis diagnostics: the Xpert MTB/RIF assay and future prospects for a point-of-care testDetection of Mycobacterium tuberculosis in blood by use of the Xpert MTB/RIF assay.Using Xpert MTB/RIFHas the answer to diagnosing TB in resource-limited settings been found?Performance of Xpert MTB/RIF RUO assay and IS6110 real-time PCR for Mycobacterium tuberculosis detection in clinical samples.Tuberculosis diagnostics and biomarkers: needs, challenges, recent advances, and opportunities.Mycobacterium diagnostics: from the primitive to the promising.Sample-to-result molecular infectious disease assays: clinical implications, limitations and potential.Diagnosis of Mycobacterium tuberculosis using molecular biology technology.Magnetic barcode assay for genetic detection of pathogens.Peripheral clinic versus centralized laboratory-based Xpert MTB/RIF performance: Experience gained from a pragmatic, stepped-wedge trial in Botswana.Suitability of Xpert MTB/RIF and genotype MTBDRplus for patient selection for a tuberculosis clinical trial.φ(2)GFP10, a high-intensity fluorophage, enables detection and rapid drug susceptibility testing of Mycobacterium tuberculosis directly from sputum samples.Evaluation of the Efficiency of the Sample Inactivation Reagent in the Abbott RealTime MTB Assay for Inactivation of Mycobacterium tuberculosis.
P2860
Q22241307-59ECAE13-13B4-4260-878C-BC845066807DQ24200879-ABFA2135-142C-4525-8BB5-5184721844D8Q24201466-5300B2D6-73EB-4383-8311-7B76F20F82B9Q24203927-5BFA35C1-7AA3-4ACC-8B15-E7E81583E935Q27004667-FEB40347-A23E-4BCC-A469-07556EF2829AQ28533713-8A72341F-873A-46F3-AF13-2F29F8151C5AQ29615717-F34A1DCB-7B30-4A34-80A4-70C732DA7453Q29617127-3CA213E7-D5BF-4D46-BF5E-37191A0CAF41Q33703605-4BAB4AC0-F6B4-4B50-90BC-54CCD38F7808Q33767720-0AAD5BFC-6CBA-4CED-9CD7-7E0A3B1E5ABBQ34384993-1832E005-A643-486A-BD22-1C9A8ECFC62BQ34584703-92671FAA-F84E-471F-91D4-1FA4188BEB84Q34974595-C9161AE9-A17A-4A47-8531-A3D5A4ED436EQ35073777-1916A02A-BCC4-4497-BE9B-0524138B53D4Q35139738-6C54A321-2AED-407C-8FC1-8D86B2C5B9F3Q35140095-8C9C910E-91F2-4A06-9B36-4613222CDF4BQ35531476-F1F9F68E-4EDA-420B-931F-1B9A1E2C9D40Q35639154-749C1EF6-D091-42A9-8F14-DCEEABFB68E0Q35868619-DCB31CD2-3665-4EDF-83E9-B4EE42C7F24BQ36100081-B9563B0D-E93F-4810-AF1D-E709CE669473Q36424212-31A1E27F-955D-48F9-94B3-89E634F22786Q36454787-C0E219F7-C4C2-4744-90E1-0DEEE4C314CCQ36501101-F37926D9-8350-49BA-ACCF-4EE4A22B9594Q36671821-4806119C-7B75-43A0-B039-F5E76CDDB6BAQ36715814-D5019141-ABD7-458D-B296-2189DE9899DAQ36797601-9C65C35B-932D-42E8-8893-4888D0914D8DQ36833723-41C5DE08-631F-405B-A467-75C3020BA26FQ36971071-177C2193-316E-465F-9858-36D71F69C6D9Q37202392-3DDB6368-80CE-4192-97A2-5BEA1708EDE4Q37205385-8CF11C1E-F1F2-48EF-B9E3-EADFD1BFC6AEQ37919272-F713B347-061A-4330-9B8C-DC1CF34D9EFDQ38002002-3AAECF94-875F-43DB-AE60-CAAA551F84D8Q38438695-96E93A24-28BD-4B8A-815C-FFDF8D0A7267Q38675080-88CE5FDE-58DF-44B2-B801-D88C14ECEDADQ39334735-4F8B73E4-FED4-4790-B7E8-564D3A105406Q40071905-E17FEB15-A392-4CA4-BAEF-411E61C76524Q40487862-F6218980-554A-4AF9-AA40-5E8072B1A8AAQ41771157-CFBAE287-5A25-40B8-B8AF-B8EBF7D6E7BDQ41984560-31103E87-196A-4BDE-B78A-5B6EEE069649Q42145356-CF2CA1EC-8BDF-4EC8-9387-8497B297D8E6
P2860
Containment of bioaerosol infection risk by the Xpert MTB/RIF assay and its applicability to point-of-care settings.
description
2010 nî lūn-bûn
@nan
2010 թուականի Օգոստոսին հրատարակուած գիտական յօդուած
@hyw
2010 թվականի օգոստոսին հրատարակված գիտական հոդված
@hy
2010年の論文
@ja
2010年論文
@yue
2010年論文
@zh-hant
2010年論文
@zh-hk
2010年論文
@zh-mo
2010年論文
@zh-tw
2010年论文
@wuu
name
Containment of bioaerosol infe ...... ity to point-of-care settings.
@ast
Containment of bioaerosol infe ...... ity to point-of-care settings.
@en
type
label
Containment of bioaerosol infe ...... ity to point-of-care settings.
@ast
Containment of bioaerosol infe ...... ity to point-of-care settings.
@en
prefLabel
Containment of bioaerosol infe ...... ity to point-of-care settings.
@ast
Containment of bioaerosol infe ...... ity to point-of-care settings.
@en
P2093
P2860
P356
P1476
Containment of bioaerosol infe ...... lity to point-of-care settings
@en
P2093
David Alland
Kevin Fennelly
Mark D Perkins
Robert Blakemore
Satheesh K Sivasubramani
P2860
P304
P356
10.1128/JCM.01053-10
P407
P577
2010-08-18T00:00:00Z